Answers are grounded in this paper and cite their sources.
Highlights the urgent need for rapid, full-dose implementation of effective therapies in acute heart failure to reduce the >30% early readmission and mortality rates.
Acute heart failure is a common and increasingly prevalent condition, affecting >10 million people annually. For those patients who survive to discharge, early readmissions and death rates are >30% everywhere on the planet, making it a malignant condition. Beyond these adverse outcomes, it represents one of the largest drivers of health care costs globally. Studies in the past 2 years have demonstrated that we can induce remissions in this malignant process if therapy is instituted rapidly, at the first acute heart failure episode, using full doses of all available effective medications. Multiple studies have demonstrated that this goal can be achieved safely and effectively. Now the urgent call is for all stakeholders, patients, physicians, payers, politicians, and the public at large to come together to address the gaps in implementation and enable health care providers to induce durable remissions in patients with acute heart failure.
No takes yet. Share an insight, caveat, or question.
Cotter et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: